The Company estimates that: ZTlido gross sales for the fiscal year ended December 31, 2023 were in the range of $145M to $150M, compared to $96M for the fiscal year ended December 31, 2022, representing growth in the range of approximately 51% to 56%. ZTlido net sales for the fiscal year ended December 31, 2023 were in the range of $46M to $52M compared to $38.0 million for the fiscal year ended December 31, 2022, representing growth in the range of approximately 21% to 37%. Total product gross sales for the fiscal year ended December 31, 2023 were in the range of $150M to $155M, compared to $96M for the fiscal year ended December 31, 2022, representing growth in the range of approximately 56% to 61%. Total product net sales for the fiscal year ended December 31, 2023 were in the range of $46.5M to $52.5M, compared to $38M for the fiscal year ended December 31, 2022, representing growth in the range of approximately 22% to 38%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SCLX:
- Scilex Holding Company Announces Filing of a New Drug Submission (NDS) to Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada
- Scilex files NDS to Health Canada division for approval of ELYXYB
- Scilex files $500M mixed securities shelf
- Scilex’s ZTlido most prescribed non-opioid pain treatment by pain specialists
- Scilex Holding Company Announces Results from Market Research with Rheumatologists Reveal a High Degree of Interest in Gloperba® as a Liquid Colchicine Formulation Designed for Precision Dosing